Back to the main directory
EarningsReview / Equity
- CCBA acquisition and Q3 sales update by BNP Paribas Exane
- OVH Groupe - Octave Klaba reprend les affaires en main by MidCap Partners
- Interparfums - INTERPARFUM confirm its topline guidance by MidCap Partners
- Potential Secondaries M&A? by BNP Paribas Exane
- BHP, S32, LITHIUM, EU ETS, US CONTRACTS, STLD, CLF, SSAB, MT by BNP Paribas Exane
- Selected upwards price pressures from Nexperia supply chain disruption by BNP Paribas Exane
- Solid message on the conference call by BNP Paribas Exane
- Corporate contact: feedback by BNP Paribas Exane
- CCBA deal & Q325 sales call: all about growth by BNP Paribas Exane
- Downgrading on valuation, shares are reasonably priced by BNP Paribas Exane
- Giving Away the Golden Goose; Downgrade to Underperform by BNP Paribas Exane
- More Multiple than Megawatt Momentum; Downgrade to Underperform by BNP Paribas Exane
- Q3 25: earnings momentum turning by BNP Paribas Exane
- Haid Group (002311 CH) by HSBC
- OVH slides after FY25: is there a read across for IONOS? by BNP Paribas Exane
- Wallenstam - Growing NAV with high-quality, low-yielding assets by Danske Bank Equity Research
- SMR, FLNC, AMRC Downgrades, Fed Permit Solar Cancellation, Doosan Risk, NXT & GEV 3Q Print + Investor Day by BNP Paribas Exane
- Racing Force - STRONG TOP-LINE PERFORMANCE ACROSS ALL REGIONS by Equita Sim
- Hologic agrees to PE take-private for up to $79/share by BNP Paribas Exane
- Preliminary Q3 results and impressive new CEO by BNP Paribas Exane
- Non material data changes by BNP Paribas Exane
- New CDMO agreement with Roche by BNP Paribas Exane
- Corporate contact: Key takeaways by BNP Paribas Exane
- Getinge - Another display of being reformed by Danske Bank Equity Research
- 3Q preview and model update by BNP Paribas Exane